Tuberculosis vaccine - Genesis Research and Development

Drug Profile

Tuberculosis vaccine - Genesis Research and Development

Alternative Names: MED-1

Latest Information Update: 08 Nov 2010

Price : $50

At a glance

  • Originator Genesis Research and Development
  • Class Antituberculars; Recombinant fusion proteins; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 08 Nov 2010 Tuberculosis vaccine - Genesis Research and Development is available for licensing as of 14 Mar 2008. http://www.genesis.co.nz/
  • 14 Mar 2008 MED-1™ technology is available for licensing (http://www.genesis.co.nz)
  • 15 Apr 2003 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top